Merck & Co. stock price

Merck & Co. has become a focal point in recent financial discussions, with its stock experiencing a decline of 11.6% over the past month, compared to a 6.5% drop in the broader market. Despite this, Jim Cramer has expressed strong confidence in Merck, suggesting it as a buy due to the leadership of CEO Robert Davis. However, the company's short interest has risen by 5.43%, indicating increasing bearish sentiment among investors, though it still has lower short interest compared to its peers. Merck's debt levels are significant, with a net debt of approximately $28.6 billion, raising concerns about financial stability, though its large market capitalization of $291.8 billion suggests these liabilities may not be immediately threatening. Analysts are closely watching Merck's earnings projections, which have seen downward revisions, impacting its perceived fair value. Overall, while Merck faces challenges, its strong market position and leadership may offer potential recovery prospects.